Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

This study tests whether giving chemotherapy directly into the artery supplying the liver (called transarterial chemoinfusion or TAI) before a liver transplant can help people with liver cancer (hepatocellular carcinoma) whose tumors are too large to normally qualify for transplant. The aim is to shrink the tumors enough to make transplant safer and more successful. **You may be eligible if...** - You are between 18 and 75 years old and on the liver transplant waiting list - You have confirmed hepatocellular carcinoma (liver cancer) that is beyond the standard size criteria for transplant (Milan or UCSF criteria) - You have not received any prior treatment for your liver cancer - There is no spread to other organs - Your liver function and blood counts are within acceptable ranges **You may NOT be eligible if...** - You cannot tolerate the arterial infusion procedure or liver transplant surgery - Your cancer has spread to distant organs - You have another active cancer - You have HIV, significant drug or alcohol abuse - You have had recent serious bleeding or a stroke/heart attack within 30 days - You are pregnant Talk to your doctor to see if this trial is right for you.